GO
Loading...

DIARY-U.S. FDA advisory meetings through April 1

Feb 21 (Reuters) - *THIS DIARY IS FILED AS THE FOOD AND DRUG ADMINISTRATION UPDATES ITS SCHEDULE. ALL TIMES IN EDT.

For more information on the FDA's Advisory Committee meetings, see: http://www.fda.gov/AdvisoryCommittees/Calendar/default.htm

MEDICAL DEVICES ADVISORY COMMITTEE MEETING

DATE: MARCH 12, 08:00-18:00

LOCATION: College Park Holiday Inn, Ballroom, 10000 Baltimore Ave., College Park, Md.

CONTACT: Shanika Craig, 301-796-6639, shanika.craigzfda.hhs.gov

AGENDA: The committee will discuss, make recommendations, and vote on a premarket approval application for a new indication for the cobas Human Papillomavirus (HPV) Test, sponsored by Roche Molecular Systems Inc, a unit of Roche Holding AG . Roche is seeking a claim whereby the cobas HPV Test can be used as a first-line primary cervical screening test.

MEDICAL DEVICES ADVISORY COMMITTEE MEETING

DATE: March 26-27, 08:00-17:00

LOCATION: Hilton Washington DC North/Gaithersburg Salons A, B, C, and D, 620 Perry Pkwy, Gaithersburg, Md.

CONTACT: Jamie Waterhouse, 301-796-3063, jamie.waterhousezfda.hhs.gov

AGENDA: The committee will discuss, make recommendations and vote on information related to the premarket approval application of Epigenomics AG for the Epi proColon, a test to screen patients for colon cancer.

ANTI-INFECTIVE DRUGS ADVISORY COMMITTEE MEETING

DATE: March 31, 08:00-17:00

LOCATION: FDA White Oak Campus, Building 31, The Great Room, 10903 New Hampshire Ave., Silver Spring, Md.

AGENDA: The committee will discuss applications for tedizolid phosphate tablets and tedizolid phosphate injection, submitted by Trius Therapeutics for the treatment of acute bacterial skin and skin structure infections. Trius was bought by Cubist Pharmaceuticals Inc in July last year.

During the afternoon session, the committee will discuss dalbavancin hydrochloride for injection, submitted by Durata Therapeutics to treat acute bacterial skin and skin structure infections.

ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEETING

DATE: April 1, 08:00-17:00

CONTACT: Karen Abraham-Burrell, 301-796-9001, EMDACzfda.hhs.gov

LOCATION: The Marriott Inn and Conference Center, University of Maryland University College (UMUC), Potomac Ballroom 3501 University Blvd. East, Hyattsville, Md.

AGENDA: The committee will discuss Mannkind Corp's inhaled insulin drug-device combination, which is intended to improve glycemic control in adult patients with type 1 or type 2 diabetes mellitus.

(Compiled by Vrinda Manocha in Bangalore; Editing by Savio D'Souza)